Amneal closes $375M cash-plus-stock acquisition of Kashiv BioSciences

Amneal Pharmaceuticals, Inc.

Closed Aug 10, 2026; paid $375M cash plus 28,942,098 Class A shares (fractional adjustment).
Sellers eligible for up to $350M in U.S. regulatory milestone payments for six Kashiv candidates.
12-year royalty tail: 25% of gross profits above hurdle amounts for certain products.
Funded partly via new $350M incremental term loan from Bank of America under Amended Credit Agreement.
Creates integrated global biosimilars platform; targets $300B+ biologics loss-of-exclusivity over next decade.

item 1.01 item 2.01 item 2.03 item 3.02 item 7.01 item 9.01

Featured in Daily 8-K Digest

Selected #2 for 2026-08-10. Read digest

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.